Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 19, 2006

Luminex and Exiqon to Work Together on microRNA Products

  • Luminex® and Exiqon signed an agreement to co-develop and commercialize microRNA products. Exiqon will develop and manufacture microRNA products on behalf of the Luminex Bioscience Group, based on Luminex’ xMAP® technology and Exiqon’s Locked Nucleic Acid (LNA™) technology.

    LNAs are a class of nucleotide analogue that binds strongly to RNA and DNA targets. By including LNAs in detection probes, it is possible to design specific high-affinity detection assays for small RNA targets like miRNAs, which otherwise would not be possible using standard DNA-based detection probes.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »